| scholarly article | Q13442814 |
| P50 | author | Franca Marino | Q88230297 |
| P2093 | author name string | Adriana Lai | |
| Eliana Piantanida | |||
| Luigi Bartalena | |||
| Maria Laura Tanda | |||
| Paolo Sivelli | |||
| Emanuele Compri | |||
| Lorenza Sassi | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1333-1337 | |
| P577 | publication date | 2010-01-08 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study | |
| P478 | volume | 95 |
| Q57136607 | 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism |
| Q41592139 | A 2013 European survey of clinical practice patterns in the management of Graves' disease |
| Q50957252 | A questionnaire survey on the management of Graves' orbitopathy in China: A comparison with Europe and Latin-America. |
| Q89620715 | Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy |
| Q38152621 | Diagnosis and management of Graves disease: a global overview |
| Q41828250 | Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. |
| Q34474593 | Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves' orbitopathy: A randomized controlled trial |
| Q38218911 | Extrathyroidal manifestations of Graves' disease: a 2014 update |
| Q26782424 | Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management |
| Q37582446 | Graves' orbitopathy: imperfect treatments for a rare disease |
| Q38869637 | Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any). |
| Q37772737 | Pathogenesis of Graves' orbitopathy: a 2010 update. |
| Q38177287 | Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature |
| Q38099144 | Prevalence and natural history of Graves' orbitopathy in the XXI century |
| Q38843328 | Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis |
| Q35830997 | Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. |
| Q48271628 | Secondary and tertiary preventions of thyroid disease |
| Q26749195 | THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy |
| Q36811289 | The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy |
| Q38107399 | The Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. |
| Q26862144 | The evaluation and treatment of graves ophthalmopathy |
| Q35725329 | The evolving role of selenium in the treatment of graves' disease and ophthalmopathy |
| Q37991056 | Thyrotoxicosis |
| Q37467757 | Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer. |
| Q37992118 | Treatment options for Graves' orbitopathy |
Search more.